Adding patient-reported outcomes data to clinician-reported adverse events in early cancer drug trials could better inform dose selection and optimization, US Food and Drug Administration officials said at a recent meeting on optimizing dose selection strategies.
PROs often are included only in late-stage or registrational cancer trials, but it is both feasible and advantageous to measure such outcomes during the dose optimization stage, said Vishal Bhatnagar, associate director
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?